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REVIEW
Abstract: Autoimmune bullous diseases result from an immune response to molecular
components of the desmosome or basement membrane. Bullous diseases are associated with
a high degree of morbidity and occasional mortality. Therapy of bullous diseases consists of
suppressing the immune system, controlling inflammation and improving healing of erosions.
The therapeutic agents used in the treatment of bullous diseases may be associated with high
morbidity and occasional mortality. Successful treatment requires understanding of the
pathophysiology of the disease process and the pharmacology of the drugs being used.
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Introduction
The autoimmune bullous diseases are a group of skin disorders that result from
autoimmunity against intercellular adhesion molecules or components of the basement
membrane in the skin and mucosal surfaces. Desmosomal proteins have important
function in intercellular adhesion. Autoimmunity to desmosomal proteins results in
various forms of pemphigus (Beutner and Jordon 1964; Anhalt et al 1982; Roscoe et
al 1985; Eyre and Stanley 1988; Amagai et al 1991; Rappersberger et al 1992; Karpati
et al 1993; Stanley 1993). Evidence from in vitro studies as well as animal models of
pemphigus in mice supports the hypothesis that pemphigus antibodies result in loss
of cellular adhesion and, hence, blister formation by directly interfering with
desmosomal function (Amagai et al 1992, 1994, 2000). The bullous diseases that
result from autoimmunity to components of the basement membrane (Stanley 1989;
Diaz and Giudice 2000) are secondary to activation of the complement system that
leads to an influx of inflammatory cells (Liu et al 1993, 1997). The specific molecules
that are the target of the autoimmune response in bullous diseases are shown in Table
1. The diagnosis of autoimmune bullous diseases is based on clinical, histologic and
immunofluorescence findings. Histologic examination of an early intact vesicle
usually reveals the characteristic findings. Direct immunofluorescence is performed
on normal skin adjacent to a lesion. Indirect immunofluorescence is performed on
the patient’s serum (Mutasim and Adams 2001).
The discussion about pharmacologic agents in this article is for off-label use. The
drugs have not been approved for the treatment of autoimmune bullous diseases and
they have not been evaluated by double-blind placebo-controlled studies. There are
multiple reasons for the lack of controlled studies. They include the rarity of
autoimmune bullous disorders, the potentially serious morbidity associated with most
cases and the ethical dilemma of withholding treatment (placebo) to a patient with a
serious disorder. The quality of evidence-based practice guidelines is therefore
variable. Most data are derived from case reports and case series. Critical interpretation
of the literature as well as reporting the personal experience of the author with a
large number of patients will be presented (Mutasim 2004).
Therapy of pemphigus vulgaris
Pemphigus vulgaris (PV) autoantibodies are directed against desmoglein III (DG
III), a component of the desmosomes that are essential for intercellular adhesion in
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skin and stratified squamous epithelium. Experimental
evidence confirms the hypothesis that PV antibodies induce
lesions by directly disrupting the function of desmosomes.
For example, passive transfer of immunoglobin G (IgG)
from PV patients induces blister formation in neonatal mice
(Anhalt et al 1982). Passive transfer of immunoglobulin
fractions that have been immunoabsorbed with pemphigus
antigen do not cause blister formation (Amagai et al 1994).
Inactivation of DG III in a knock-out mouse model results
in lesions similar to those in patients with PV (Koch et al
1997). The above evidence indicates that antibodies to DG
III result in incomplete assembly or disruption of
desmosomes, followed by loss of intercellular adhesion and
blister formation. The role of therapy in patients with PV is
to suppress the immune system and prevent the production
of the pathogenic antibodies. This would result in healing
of existing lesions and prevention of the appearance of new
lesions. Immunologic remission is indicated by a significant
decrease or absence of pathogenic antibodies in the serum
and skin of patients with PV. There has been a significant
decrease in the mortality of patients with PV since the
availability of glucocorticoids and, later, non-steroidal
immunosuppressive drugs. Prior to the availability of these
drugs, the mortality rate due to the disease was 50%.
Presently the mortality rate is less than 10% and is primarily
due to complications of therapy.
The choice of therapy depends only to a slight degree
on the severity of the disease at presentation. The usual
course of PV is unrelenting and progressive. Hence, patients
who present with limited disease may still be treated
“aggressively”. Unless there is an absolute contraindication,
the initial drug is a systemic glucocorticoid. Topical and
intralesional glucocorticoids have also been used in the
treatment of mild PV (Bystryn and Steinman 1996; Dumas
et al 1999), however, they are rarely effective.
Both prednisone and methylprednisolone may be used.
The starting dose of prednisone is 1mg/kg/day divided into
two or three doses. An equivalent dose of
methylprednisolone may be substituted. Depending on the
severity of the disease and its duration, patients obtain a
clinical remission within 4–12 weeks. This is usually
accompanied by a decrease in the amount, or absence, of
circulating PV antibodies in the patient’s serum. The dose
is maintained for 6–10 weeks in order to further suppress
the immune response. If the patient remains in clinical
remission, the dose is then decreased by 10–20 mg every
2–4 weeks. When the dose is 40 mg daily, dosing may be
changed to every other day. This transition may be
accomplished by doubling the dose to 80 mg daily, followed
by a day with no treatment (80 mg on alternate days). The
dose is then gradually decreased. Alternatively, the transition
may be accomplished (author’s preference) by keeping the
first day dose at 40 mg and decreasing the next day’s dose
by 5–10 mg every 2–4 weeks. When the dose is 40 mg every
other day, it may be tapered by 5 mg every 2–3 weeks. If
there is no recurrence, the patient is maintained on 5 mg
daily for several years in order to avoid recurrences.
In patients who have severe disease or who are not
responding adequately to the standard dose of prednisone,
the dose may be increased to 1.5 or 2 mg/kg/day until
remission. Alternatively, intravenous methylprednisolone 1 g
daily may be given for three consecutive days. This
procedure is referred to as pulse-steroid therapy. Its goal is
to achieve a rapid immunosuppressive effect of the
glucocorticoid while avoiding the long term side effects
(Werth 1996).
“Adjuvant immunosuppressive therapy” refers to the
addition of a non-steroidal immunosuppressive agent to the
glucocorticoid. Adjuvant therapy may be used in two ways.
First, it may be used in patients who fail to obtain a remission
or who experience serious adverse effects secondary to
glucocorticoid therapy. Second, it may be used
concomitantly with glucocorticoid therapy to decrease the
total dose of glucocorticoid needed and, hence, the adverse
effects. The concomitant use of adjuvant therapy allows the
glucocorticoid dose to be tapered rapidly. Patients are
maintained on the “steroid-sparing” agent for 18–24 months.
The most commonly used steroid-sparing
immunosuppressive agents are azathioprine, mycophenolate
mofetil (MMF), and cyclophosphamide.
Azathioprine is likely the most commonly used steroid-
sparing agent world wide. In a review (Bystryn and Steinman
1996) of seven studies involving 105 patients, remissions
Table 1 Molecular classification of bullous diseases
Bullous disease Targeted molecule/organelle
Pemphigus vulgaris Desmoglein III 
Pemphigus foliaceous Desmoglein I
Paraneoplastic pemphigus Desmoplakin I, Desmoplakin II,
BP 230, Envoplakin, Periplakin,
Desmoglein III, Plectin, Other
IgA Pemphigus Desmocollin I
Bullous pemphigoid BP 180, BP 230 
Mucous membrane pemphigoid BP 180, laminin 5 
Epidermolysis bullosa acquisita Type VII collagen 
Dermatitis herpetiformis Unknown
Abbreviations: BP, bullous pemphigoid ; IgA, immunoglobin A.Therapeutics and Clinical Risk Management 2007:3(1) 31
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were induced in 28% of patients. Azathioprine is usually
well tolerated. It is a purine analog. The usual dose is 3–
4 mg/kg/day that may be taken once daily or in divided
doses. Azathioprine is metabolized through multiple
pathways. One pathway involves an enzyme (thiopurine
methyltransferase [TPMT]) whose level varies among
individuals. It is deficient in approximately 1 in 300
Caucasian individuals. The dose of azathioprine is usually
adjusted to the level of TPMT. Individuals with absent
TPMT should not receive azathioprine. Individuals with high
levels of TPMT may require relatively high doses of the
drug. Azathioprine is well tolerated. It may result in
gastrointestinal intolerance, mild hepatotoxicity, and bone
marrow suppression (commonly of the leukocyte series).
Azathioprine should not be given to women who are
considering becoming pregnant.
MMF is a relatively safe steroid-sparing agent that was
first used for PV in 1997 (Enk and Knop 1997). Its use was
later reported (Enk and Knop 1999) in 12 patients who failed
combination therapy with prednisone and azathioprine. The
dose of MMF used was 1 g twice daily. Eleven of the 12
patients had improvement without relapse during a 9–12
month follow-up period. MMF has recently been reported
to be effective as monotherapy (Bredlich et al 1999;
Grundmann-Kollman et al 1999). Other reports have
confirmed the efficacy of MMF as adjuvant therapy in the
treatment of PV (Mimouni et al 2003). MMF is a purine
analog antimetabolite whose kinetics and metabolism show
great intra-individual and inter-individual variability. It is
usually well tolerated. Adverse effects include occasional
gastrointestinal upset and mild dose-related bone marrow
suppression.
Cyclophosphamide is an alkylating cytotoxic agent that
is a highly effective steroid sparing agent. In a review
(Bystryn and Steinman 1996) of five studies with a total of
51 patients, complete remission was achieved in 32% of
patients. The rate of remission for each of the five studies
that were reviewed was very wide (0%–80%), reflecting
the small number of patients in each study.
Cyclophosphamide has been used as pulse therapy (1 g
intravenously every four weeks) (Fellner and Sapadin 2001).
This therapy produces much less adverse effects and may
be equally effective in some patients. Immunoablative high
dose cyclophosphamide (50 mg/kg intravenously daily for
four consecutive days) without stem cell rescue has been
advocated and reported to be effective in resistant cases
(Hayag et al 2000; Nousari et al 2003). Cyclophosphamide
alkylates DNA at various sites, resulting in cell cycle arrest,
DNA repair and cell death. Proliferating tissues are most
susceptible to its effect. The toxicity of cyclophosphamide
is significantly higher than that of azathioprine and MMF.
Acute myelosuppression is common (nadir at 6–10 days
and recovery in 14–21 days). Other adverse effects include
mucosal ulcers, alopecia, nephrotoxicity, urotoxicity
(hemorrhagic cystitis), cardiotoxicity, hepatotoxicity,
interstitial lung fibrosis, and toxicity in reproductive systems
resulting in amenorrhea that may be permanent, and
azoospermia that may be reversible. Cyclophosphamide is
mutagenic and carcinogenic and its long term use has been
associated with acute non-lymphocytic leukemia.
Methotrexate is a generally less effective steroid-sparing
agent in the treatment of PV. Nine patients (Smith and
Bystryn 1999) with steroid-dependent PV underwent the
addition of oral methotrexate (starting at 7.5 mg weekly and
increasing by 2.5–5 mg every two weeks as needed). Six of
the nine patients underwent significant improvement that
allowed the glucocorticoid to be discontinued. Upon
discontinuing methotrexate, however, the disease flared
(mean duration 23 days). In the author’s judgment,
methotrexate use may be attempted only if there are
contraindications to the use of other more effective steroid-
sparing agents. Methotrexate is an antimetabolite and a folic
acid analog. Its toxicity may affect multiple organs including
the bone marrow (suppression), gastrointestinal epithelium
(ulcers), hair follicles (alopecia), kidneys (nephrotoxicity),
lungs (interstitial pneumonitis), liver (hepatitis and
cirrhosis), and reproductive organs (defective
spermatogenesis and oogenesis).
The response of PV to cyclosporine is not clearly
understood and is not as predictable as that to azathioprine,
MMF or cyclophosphamide (Thivolet et al 1985;
Barthelemey et al 1988; Alijotas et al 1990; Lapidoth et al
1994; Mobini et al 1997; Ioannides et al 2000). In a report
(Thivolet et al 1985) of two patients who were not responsive
to prednisone 1 mg/kg/day, the addition of cyclosporine
6mg/kg/day resulted in improvement 10–15 days after
initiation of therapy. Another report (Alijotas et al 1990)
confirmed a response of severe PV in two siblings to
cyclosporine monotherapy. The addition of cyclosporine
(initial dose 5 mg/kg day, adjusted to achieve blood levels
of 100–150 ng/ml) in 16 patients who were also taking
prednisone 60–80 mg daily resulted in a reduction of the
time to new blister formation, the mean total dose of
prednisone needed, and the duration of hospital stay
(Lapidoth et al 1994). The control group consisted of 15
patients who were treated with high dose prednisoneTherapeutics and Clinical Risk Management 2007:3(1) 32
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(120 mg daily). Cyclosporine (1–3 mg/kg day adjusted to
obtain a serum level of 100–125 ng/ml) was highly effective
in a group of six patients with severe PV who were
unresponsive to multiple previous therapies including
glucocorticoids, azathioprine, cyclophosphamide, dapsone,
gold and methotrexate (Mobini et al 1997). Near complete
clinical remission was obtained by 20 weeks. No recurrences
occurred during a 3.5–5 year follow-up period during which
no systemic treatment was given. Finally, the addition of
cyclosporine to glucocorticoid was shown to be ineffective
in a group of 33 patients hospitalized with PV (Ioannides et
al 2000). In conclusion, cyclosporine may be effective for
selected patients. Its use may be attempted in patients who
have failed other immunosuppressive therapies.
Cyclosporine potently suppresses cellular immunity and
preferentially inhibits antigen-triggered signal transduction
in T lymphocytes. This results in decreased expression of
several lymphokines, especially interleukin-2. The drug is
excreted through bile as metabolites. The dose of
cyclosporine needs adjustment in patients with liver failure
but not in patients with renal failure. Cyclosporine may be
associated with elevation of blood pressure, blood creatinine
level, short term as well as long term renal dysfunction,
hirsutism, gingival hyperplasia, hyperlipidemia, and
neurologic side effects including tremors.
High dose intravenous immunoglobulin (IVIg) has been
reported to be of benefit as a steroid-sparing agent in the
management of patients with PV. In a review of eight reports
(Engineer et al 2000), high dose IVIg was effective in 17 of
18 patients. High dose IVIg should be used as adjuvant to
conventional therapy, that is, as a steroid-sparing agent
(Colonna et al 1998). In a recent report, 21 patients with
severe PV who were unresponsive to treatment with
prednisone and multiple immunosuppressive drugs were
treated with high dose IVIg (Ahmed 2001). Each cycle
consisted of the infusion of a total of 2 g/kg body weight
over four or five days. All patients obtained clinical
remission after a mean duration of 4.46 months. All patients
remained in remission after a mean duration of maintenance
therapy of 22.7 months and after a mean follow-up period
of 20 months following discontinuation of therapy. In
another recent report (Bystryn et al 2002), six patients with
PV who were unresponsive to conventional therapy were
treated with high dose IVIg concurrently with
cyclophosphamide. Significant and rapid improvement of
their disease was observed. High dose IVIg is a purified
human source of IgG from pooled plasma (Mackay and
Rosen 2001). The agent was originally used in small doses
for the treatment of congenital immune deficiencies. It is
given in a high dose (2 g/kg/cycle) for autoimmune diseases.
It is administered as slow infusion up to eight hours. If there
is history of previous allergic reaction, the patient is pre-
medicated with steroids or antihistamine. Treatment is
repeated every 3–4 weeks until remission occurs. The
mechanism of action is unknown. Adverse effects are rare
and include fever, headache, myalgia, nausea, tachycardia,
dermatitis (Mutasim and Sheth 2002), renal failure, and
stroke.
Plasmapheresis consists of withdrawing the patient’s
blood, using a filter to separate the cellular elements, and
returning them to the patient. This procedure results in the
removal of the pathogenic antibodies. Its use is usually
limited to patients with severe autoimmune disorders. The
effectiveness of plasmapheresis, however, is controversial.
One study (Guillaume et al 1988) did not find the addition
of plasmapheresis to prednisone to be superior to prednisone
alone. In another study (Tan-Lim and Bystryn 1990), the
addition of plasmapheresis to prednisone (with
cyclophosphamide or azathioprine) resulted in a marked
decrease in the level of circulating antibodies and decreased
disease activity. In order to avoid the rebound phenomenon
(patients producing more pathogenic antibodies immediately
following plasmapheresis), concomitant use of
immunosuppression, preferably with cyclophosphamide, is
indicated (Turner et al 2000; Fellner and Sapadin 2001). In
conclusion, plasmapheresis in combination with
cyclophosphamide may be a valuable treatment for patients
with severe disease who are unresponsive to conventional
therapy.
Gold is available in parenteral and oral forms. The
parenteral forms are completely absorbed, have a half-life
of six days and are 70% excreted in the urine. The oral form
is 25% absorbed with a half-life of 21 days and is excreted
through the hepatobiliary tract. The commonly used dose is
10 mg intramuscularly initially, then a 25 mg injection one
week later. If there are no adverse effects (see later), 50 mg
weekly injections are given subsequently. Oral gold is started
at 3 mg twice daily, up to 9 mg daily. When remission is
obtained, the dose is decreased and maintained at the lowest
dose that keeps the patient in remission. The onset of action
is slow with the beneficial effect usually requiring six
months of therapy to be appreciated. Gold is usually given
concomitantly with glucocorticoids followed by tapering
and discontinuation of the glucocorticoid. Patients who
undergo remission are maintained on gold (Salomon and
Saurat 1986). In a series of 13 patients (Poulin et al 1984)Therapeutics and Clinical Risk Management 2007:3(1) 33
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who were treated with prednisone and gold, seven had
complete remission that required no further treatment. Two
patients had recurrences three and five months after
discontinuing gold therapy. In another report (Pandya and
Dyke 1998), 85% of 26 patients with pemphigus (21 of
whom had PV) responded to therapy. Only four (15%),
however, attained complete remission. In seven patients,
prednisone was discontinued and the patients continued to
be in remission while on gold therapy alone. Complications
of therapy developed in 42% of patients. The efficacy of
gold is generally inferior to that of immunosuppressive
drugs. It may be especially useful as maintenance therapy,
as well as in patients in their reproductive years because it
lacks the carcinogenic and gonadal effects of most other
immunosuppressive drugs. The mechanism of action of gold
is unknown.
Dapsone has been used by some as an adjunct in therapy
of patients with mild PV. There is greater support for its
efficacy in another form of pemphigus (pemphigus foliaceus
[PF]). Of six patients with pemphigus (both PV and PF)
treated with dapsone 100–300 mg daily in combination with
prednisone, three (type unspecified) had improvement
(Bystryn 1984). Further support for the possible role of
dapsone is based on a report (Jablonska and Chorzelski
1981) that described a few patients with PV who underwent
full remission after the addition of dapsone 100 mg to their
previous therapy of glucocorticoid and methotrexate. The
small number of cases reported in both series prevents
making definitive conclusions about the role of dapsone in
the treatment of PV. Dapsone is the prototypic example of
the sulfone group of drugs whose mechanism of action is
unclear. It inhibits neutrophil chemotaxis. It causes a dose-
dependent hemolysis that occurs in 100% of patients who
receive a dose equal to or more than 200 mg daily. Patients
who are deficient in the enzyme glucose-6-phosphate
dehydrogenase are more prone for hemolysis. Met-
hemoglobulinemia is common and may be severe in patients
deficient in Met-hemoglobin reductase. Agranulocytosis is
a rare, idiosyncratic reaction that occurs within the first three
months of therapy. Agranulocytosis is a serious adverse
effect that occurs in approximately 1 in 300 individuals.
Other adverse effects of dapsone include anorexia, headache,
nervousness, peripheral neuropathy, hematuria, hepatitis and
multiple skin eruptions.
Extracorporeal photochemotherapy (ECP) is a form of
immunotherapy that was first approved for the treatment of
cutaneous T cell lymphomas. The patient ingests a photo-
activating agent (methoxypsoralen) 1.5 hours prior to the
procedure. Peripheral blood is collected within the ECP unit.
A small portion of the peripheral lymphocyte pool is isolated
and exposed to ultraviolet A light. Treated lymphocytes
along with other cellular and plasma components are
reinfused into the patient. The procedure lasts approximately
three hours and is repeated the next day. The patient is given
a cycle every four weeks. The precise mechanism of action
of ECP is unknown. ECP is reserved for patients with PV
who fail drug therapy. In 1990, four patients were reported
who received glucocorticoid and immunosuppressive
therapy along with ECP (Rook et al 1990). All patients
showed response to treatment. Another report describes three
patients who failed immunosuppressive agent therapy, but
who showed complete remission following ECP (Wollina
et al 1999). Because of the limited availability of ECP, its
high cost, and the lack of controlled trials, ECP is limited
for patients who have failed glucocorticoid and other
immunosuppressive therapies.
Rituximab is a chimeric monoclonal antibody against
CD20 on the surface of mature B cells and plasma cells.
Rituximab has been effectively used in the treatment of B
cell lymphomas. Its use has been reported to be beneficial
in individual cases of resistant PV (Salopek et al 2002;
Dupuy et al 2004; Espana et al 2004). The dose is 375 mg/
m
2 intravenously every week. Figure 1 is an algorithmic
approach to the treatment of patients with PV.
Management of pemphigus
foliaceus
PF is associated with lower morbidity than PV. Patients do
not have mucosal lesions (which are invariable in patients
with PV). The principals and practice of treating patients
with PF are similar to those for PV. The reader is referred to
specific literature for the management of patients with PF
(Bystryn 1984; Basset et al 1987; Hymes and Jordon 1992;
Leibowitz and Voss 1993; Bystryn and Steinman 1996).
Therapy of paraneoplastic
pemphigus
Paraneoplastic pemphigus (PNP) is a multiorgan disorder
in which patients develop a unique mucocutaneous eruption
in association with an underlying neoplasm, most commonly
of B cell lineage (chronic lymphocytic leukemia, non-
Hodgkin’s B cell lymphoma, thymoma and Castleman
disease). In general, successful treatment of the underlying
condition results in marked improvement or resolution of
the mucocutaneous bullous and erosive disorder. Skin
lesions tend to respond more rapidly than mucosal lesions.Therapeutics and Clinical Risk Management 2007:3(1) 34
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The first line agent is usually systemic glucocorticoid (1–
2 mg/kg/day). Patients tend to have a partial response
(Anhalt 1997; Dega et al 1998).
One patient with chronic lymphocytic leukemia
(Perniciaro et al 1994) was treated with cyclosporine 5 mg/
kg daily in combination with prednisone 35 mg daily. The
combination therapy resulted in marked improvement within
two months. The combination of intravenous dexamethasone
and cyclophosphamide was reported to be effective in one
patient. One patient with PNP and chronic lymphocytic
leukemia had marked improvement with high dose
cyclophosphamide therapy without stem cell rescue
(Nousari, Brodsky, et al 1999). Rituximab was effective in
a patient with PNP associated with CD20+ follicular
lymphoma (Borradori et al 2001) and a case of PNP
associated with follicular non-Hodgkin’s lymphoma
(Heizmann et al 2001). The dose is 375 mg/m
2 intravenously
every week. Significant improvement has been reported with
plasmapheresis (Fullerton et al 1992; Su et al 1994; Izaki et
al 1996). Finally, a patient who failed glucocorticoid therapy
and excision of an associated inflammatory
myelofibroblastic tumor of the upper mediastinum had
significant improvement following immunoapheresis.
Immunoapheresis is a procedure in which the pathogenic
antibodies are adsorbed by sheep anti-human IgG bead-
formed agarose gel. The patient underwent two or three
sessions per week for four weeks (Schoen et al 1998).
Therapy of bullous pemphigoid
Bullous pemphigoid (BP) results from an autoimmune
response and is mediated by a prominent cellular
inflammatory infiltrate rich in eosinophils. Unlike PV, BP
may remit spontaneously. Unlike therapy for PV, effective
treatment of BP may be accomplished with lower doses of
immunosuppressive drugs and/or anti-inflammatory agents.
Potent topical steroids should be considered and favored in
the management of localized or limited disease. In a recent
report, potent topical steroid therapy was equivalent to oral
glucocorticoid therapy for both moderate and severe BP
(Joly et al 2002). In the study, with a total of 341 patients,
the end point was overall survival at one year. In patients
with extensive BP, topical glucocorticoids resulted in a 43%
reduction in the one year mortality compared with the
prednisone 1 mg/kg/day group. This study may be criticized
as to its choice of the end point. The end point most
practitioners use is resolution of clinical disease and
maintaining remission with the least possible dose of drug
therapy.
Figure 1 Algorithmic approach to the treatment of pemphigus vulgaris.
Abbreviations: IVIg, intravenous immunoglobulin; MMF, mycophenolate mofetil.Therapeutics and Clinical Risk Management 2007:3(1) 35
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Most patients with generalized BP require systemic
therapy, the most commonly used agents being
glucocorticoids (Church 1960; Siegel and Eaglstein 1984).
Systemic glucocorticoids are usually sufficient as the sole
therapy in the majority of cases. The dose is 0.5–0.75 mg/
kg/day. Unlike patients with PV, higher doses of prednisone
are rarely needed. A clinical response is usually attained
rapidly (within 1–3 weeks) and is heralded by healing of
existing lesions and cessation of new blister formation. The
prednisone dose is then gradually tapered to 5mg daily over
a period of 5–6 months. The guidelines for the tapering
procedure are similar to those used for PV. In patients who
have high morbidity secondary to extensive skin disease,
steroid pulse therapy with methylprednisolone 1 g daily for
three consecutive days may be used for the initial rapid
control of the disease. Immunosuppressive drugs are rarely
needed in patients with BP. They may be used in patients
who require high maintenance doses of glucocorticoids, for
patients who are experiencing adverse effects from
glucocorticoids, and for those whose disease does not
respond completely to glucocorticoid therapy. The most
commonly used agents are azathioprine (Greaves et al 1971;
Burton and Greaves 1974), MMF (Nousari et al 1998;
Wojnarowska et al 2002), and methotrexate (Downham and
Chapel 1978). Cyclophosphamide is rarely indicated (Krain
et al 1972). MMF is effective both as a sole agent as well as
in combination with glucocorticoids (Nousari et al 1998;
Grundmann-Kollman et al 1999; Nousari, Brodsky, et al
1999; Nousari, Sragovich, et al 1999). The dose is usually
1 g twice daily. The dose of azathioprine is 1–3 mg/kg daily.
The dose may be adjusted based on the clinical response,
side effects and the level of TPMT. Methotrexate is effective
in relatively small doses (up to 12.5 mg weekly) as a sole
therapy (Heilborn et al 1999). Chlorambucil 2 mg daily has
been reported to result in a reduction in the amount of
glucocorticoids required for the control of BP in 23 patients
(Milligan and Hutchinson 1990). Finally, cyclosporine has
been reported to be effective in a dose of 6 mg/kg/day (in
two equal doses) (Thivolet et al 1985). In general, once the
patient who is receiving prednisone and an
immunosuppressive agent attains complete remission, the
prednisone is tapered and discontinued. The
immunosuppressive agent is maintained and ultimately
slowly tapered and discontinued.
Plasmapheresis may be used in severe cases and is
usually used in association with immunosuppressive drugs
(Roujeau et al 1984; Goldberg et al 1985). A report of 41
patients documented the steroid-sparing effect of
plasmapheresis (Roujeau et al 1984). Several years later a
similar report failed to confirm the benefit of plasmapheresis
in addition to glucocorticoid compared with glucocorticoid
alone (Guillaume et al 1993). Plasmapheresis is costly, time
consuming, and only temporarily beneficial. High dose IVIg
is highly effective in selected cases (Engineer and Ahmed
2001b). The dose is similar to that used in patients with
pemphigus. Since high dose IVIg is extremely expensive,
it should be reserved for resistant cases. A recent review of
four open, uncontrolled trials revealed that IVIg was
effective in 70% of patients (Engineer and Ahmed 2001b).
Dapsone (or sulfapyridine) has been reported to be of mild
to moderate benefit in 110 cases (Person and Rogers 1977;
Venning et al 1989; Phiamphonsongant 1993; Bouscarat et
al 1996). Dapsone is started at 50 mg daily and increased
by 50 mg increments every week until remission.
Tetracyclines (or erythromycin) with or without
niacinamide (Berk and Lorincz 1986; Thomas et al 1993)
has been used effectively in BP. In one study, the
effectiveness of tetracycline and niacinamide was compared
with that of prednisone in the treatment of generalized BP
(Fivenson et al 1994). The two therapeutic regimens were
equally effective. The dose of tetracycline was 500 mg four
times daily. It could be replaced with minocycline or
doxycycline 100 mg twice daily. The dose of niacinamide
is 500 mg three times daily. The use of a tetracycline with
niacinamide may be indicated as sole therapy for very
limited disease or as steroid-sparing in patients requiring
adjuvant therapy. A recent report attempted to determine
the evidence for treating BP from six randomized control
trials that included 293 patients (Khumalo et al 2002). The
authors could not derive any strong recommendations from
the available evidence. An attempt at creating guidelines
for treating BP have been reported (Khumalo et al 2002;
Mutasim 2002; Wojnarowska et al 2002). Systemic
glucocorticoids are the best established treatment.
Consideration should be given to potent topical steroids for
localized disease. For mild to moderate disease, a
tetracycline and niacinamide may be considered. It is
recommended that immunosuppressive agents be used only
if glucocorticoid cannot be tapered to an acceptable level.
The best established drug is azathioprine followed by
methotrexate (Khumalo et al 2002). Figure 2 is a proposed
algorithm for the treatment of BP.Therapeutics and Clinical Risk Management 2007:3(1) 36
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Therapy of mucous membrane
pemphigoid
Therapy of mucous membrane pemphigoid (MMP) varies
according to disease extent, severity and location (Anhalt
and Morrison 1991). Patients with mild oral involvement
are usually treated with topical therapy using topical
anesthetic agents to control pain, as well as topical
glucocorticoids. Oral hygiene is emphasized. The topical
glucocorticoid may be applied under occlusion with a
prosthetic device in order to increase its penetration.
Alternatively, it may be injected into the lesion. Patients
with moderate to severe oral involvement require systemic
therapy (Jabs and Anhalt 1988). Some patients respond to
dapsone (Rogers et al 1982; Rogers and Mehregan 1988;
Fern et al 1992; Elder et al 1996). Oral lesions respond more
rapidly than lesions in other mucous membranes. Treatment
is started at 50 mg daily and increased gradually as tolerated
and as needed. Because of the dose-dependent hemolysis,
the maximum dose is usually 200–300 mg daily. A
tetracycline with or without niacinamide may be effective
in some patients (Poskitt and Wojnarowska 1995; Reiche et
al 1998; Dragan et al 1999). In patients with severe oral
lesions, as well as in patients with ocular, pharyngeal, or
laryngeal involvement, a combination of systemic
glucocorticoids with a steroid-sparing agent is indicated
(Brody and Pirozzi 1977). Most patients who are treated
with prednisone 1 mg/kg/day for six months and
cyclophosphamide 1–2 mg/kg/day for 18–24 months
respond and have a prolonged or permanent remission.
Azathioprine (Dave and Vickers 1974) and MMF are
generally less effective but may be used in patients who
cannot tolerate cyclophosphamide or prednisone. Multiple
reports have documented the effectiveness of high dose IVIg
in the treatment of MMP, including patients who were
refractory to other therapies (Ahmed and Moy 1981; Foster
and Ahmed 1999; Heilborn et al 1999; Letko et al 2000;
Ahmed and Colon 2001; Mackay and Rosen 2001; Sami et
al 2002a, 2002b).
Therapy of epidermolysis bullosa
acquisita
Compared with BP, epidermolysis bullosa acquisita (EBA)
is generally resistant to therapy (Taniuchi et al 1997). The
disorder may present in one of two major forms. In type 1
EBA (mechanobullous), lesions result from minor trauma.
In type 2 (inflammatory type), a neutrophil-rich cellular
infiltrate mediates blister formation at the BMZ. Because
of the neutrophil predominance, many patients with EBA
respond to anti-neutrophil drugs such as dapsone (Taniuchi
et al 1997; Huges and Callen 2001). Dapsone is started at
50 mg daily and increased by 50 mg every week until clinical
remission or adverse effects (usually 100–250 mg daily). In
patients who are allergic to dapsone, colchicine may be of
benefit (Berbis and Privat 1989; Megahed and Scharffetter-
Kochanek 1994; Cunningham et al 1996). The response to
colchicine, however, is less predictable than that to dapsone.
The dose of colchicine may be limited by the predictable
gastrointestinal side effects (diarrhea). Patients who fail
dapsone or colchicine or who are intolerant of the drugs
may be treated with prednisone 1 mg/kg/day. The response
is variable but generally good. Cyclosporine is a very potent
steroid-sparing agent that may be used in patients who do
not respond to glucocorticoids or who develop adverse
effects. Cyclosporine is usually initiated in a dose of 4 mg/
kg/day in two equally divided doses (Engineer and Ahmed
2001a). The dose may be increased if there is only partial
response. Several dosing regimens have been reported,
ranging from 5 mg to 9 mg/kg/day (Connolly and Sander
1987; Zachariae 1987; Crow et al 1988; Gupta et al 1990;
Layton and Cunliffe 1990; Merle et al 1990; Klein et al
1991; Berger et al 1992; Clement et al 1993). Other
immunosuppressive agents such as azathioprine or
cyclophosphamide may be used. Patients who fail to respond
may be treated with IVIg alone (Kofler et al 1996) or in
combination with plasmapheresis (Taniuchi et al 1997).
Other cases have been reported with variable response to
IVIg either individually or in combination with other
immunosuppressive agents (Meier et al 1993; Caldwell et
al 1994; Mohr et al 1995; Kofler et al 1996; Jappe et al
2000). Patients with resistant disease may be treated with
plasmapheresis (Furue et al 1986) or ECP (Gordon et al
1997; Heilborn et al 1999) in addition to immunosuppressive
therapy (Gordon et al 1995; Miller et al 1995).
Therapy of dermatitis
herpetiformis
Dermatitis herpetiformis (DH) results from an immune
response to gluten. A completely gluten-free diet is
extremely helpful in the management of DH and results in
a marked decrease in the dose of pharmacologic therapy
needed. Re-exposure to gluten results in a recurrence of the
disease within a few months (Leonard et al 1983). Most
patients find a gluten-free diet to be too restrictive.
Pharmacologic therapy is aimed at the suppression ofTherapeutics and Clinical Risk Management 2007:3(1) 37
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neutrophil chemotaxis in the skin. This is accomplished with
dapsone. The initial dose is 50 mg daily to be increased every
week if needed until clearance or intolerance. The average
daily dose is 100 mg. Patients who are allergic or intolerant
of dapsone may be treated with sulfapyridine (Costello
1940). The initial dose is 500 mg three times daily and may
be increased slowly to 2 g three times daily. The response
to sulfapyridine is less predictable than that to dapsone.
Patients who are intolerant or allergic to dapsone and
sulfapyridine may be treated with colchicine (Silvers et al
1980), cholestyramine (Shelley 1980) or tetracycline and
niacinamide (Shah and Ormerod 2000). These agents,
however, are much less effective than dapsone. Finally,
topical steroids are of minimal benefit.
Skin care
Appropriate skin care is important in the healing of lesions
and avoidance of complications. After blisters rupture,
resulting erosions may become secondarily infected with
bacteria, may progress to ulcers (especially over pressure
areas such as the buttocks and the back), and may acquire
crusting that interferes with reepithelialization and healing.
Measures that help in the healing process include gentle
cleansing of the erosions, liberal application of antibiotic
ointments or petroleum jelly, and avoidance of trauma. The
elderly are especially prone to complications and may
require hospital admission for proper skin care.
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